Furthermore, genomic and transcriptomic profiling has revealed that genetic alterations and deregulated gene expression of PI3K pathway components are common in patients with prostate cancer, occurring in as many as 42% of primary and 100% of metastatic prostate cancer samples [42,43,44,45,46]. This evidence concerns the gene PIK3CA and prostate cancer.